Genetic Clonality as the Hallmark Driving Evolution of Non-Small Cell Lung Cancer

被引:8
|
作者
Nicos, Marcin [1 ]
Krawczyk, Pawel [1 ]
机构
[1] Med Univ Lublin, Dept Pneumonol Oncol & Allergol, PL-20954 Lublin, Poland
关键词
NSCLC; tumor evolution; driver mutations; clonal; subclonal alterations; metastases; STEM-CELLS; INTRATUMOR HETEROGENEITY; MESENCHYMAL TRANSITION; TUMOR EVOLUTION; BRANCHED EVOLUTION; BRAIN METASTASES; T790M MUTATION; CD133(+) CELLS; ADENOCARCINOMA; NOTCH;
D O I
10.3390/cancers14071813
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Limited knowledge about NSCLC evolution has affected therapeutic strategies for many decades. The application of NGS-based techniques to studies on ITH has provided genetic insight into the contribution of clonality primary seeding, as well as to distant dissemination. To date, multiregional ITH affects accurate diagnosis and treatment decisions and is considered the main hallmark of anticancer therapy failure. Understanding the evolutionary trajectories that drive the metastatic process is critical for improving treatment strategies for this deadly condition. In this review, we discuss how the clonality of genetic alterations influence the seeding of primary and metastatic lesions of NSCLC, highlighting that wide genetic analyses may reveal the phylogenetic lineages of NSCLC evolution. Data indicate that many driver alterations from the primary tumor of non-small cell lung cancer (NSCLC) are predominantly shared across all metastases; however, disseminating cells may also acquire a new genetic landscape across their journey. By comparing the constituent subclonal mutations between pairs of primary and metastatic samples, it is possible to derive the ancestral relationships between tumor clones, rather than between tumor samples. Current treatment strategies mostly rely on the theory that metastases are genetically similar to the primary lesions from which they arise. However, intratumor heterogeneity (ITH) affects accurate diagnosis and treatment decisions and it is considered the main hallmark of anticancer therapy failure. Understanding the genetic changes that drive the metastatic process is critical for improving the treatment strategies of this deadly condition. Application of next generation sequencing (NGS) techniques has already created knowledge about tumorigenesis and cancer evolution; however, further NGS implementation may also allow to reconstruct phylogenetic clonal lineages and clonal expansion. In this review, we discuss how the clonality of genetic alterations influence the seeding of primary and metastatic lesions of NSCLC. We highlight that wide genetic analyses may reveal the phylogenetic trajectories of NSCLC evolution, and may pave the way to better management of follow-up and treatment.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Non-small cell lung cancer - genetic predictors
    Koudelakova, Vladimira
    Kneblova, Magdalena
    Trojanec, Radek
    Drabek, Jiri
    Hajduch, Marian
    BIOMEDICAL PAPERS-OLOMOUC, 2013, 157 (02): : 125 - 136
  • [2] Evolution of non-small cell lung cancer chemotherapy (Review)
    Dimitroulis, J
    Stathopoulos, GP
    ONCOLOGY REPORTS, 2005, 13 (05) : 923 - 930
  • [3] The hypoxic tumor microenvironment: driving the tumorigenesis of non-small-cell lung cancer
    Foster, John G.
    Wong, Sybil C. K.
    Sharp, Tyson V.
    FUTURE ONCOLOGY, 2014, 10 (16) : 2659 - 2674
  • [4] Genetic changes of non-small cell lung cancer under neoadjuvant therapy
    Warth, Arne
    Endris, Volker
    Stenzinger, Albrecht
    Penzel, Roland
    Harms, Alexander
    Duell, Thomas
    Abdollahi, Amir
    Lindner, Michael
    Schirmacher, Peter
    Muley, Thomas
    Dienemann, Hendrik
    Fink, Ludger
    Morresi-Hauf, Alicia
    Pfarr, Nicole
    Weichert, Wilko
    ONCOTARGET, 2016, 7 (20) : 29761 - 29769
  • [5] Genetic testing for chemotherapy in non-small cell lung cancer
    Rosell, R
    Taron, M
    Alberola, V
    Massuti, B
    Felip, E
    LUNG CANCER, 2003, 41 : S97 - S102
  • [6] Current knowledge of small cell lung cancer transformation from non-small cell lung cancer
    Giaccone, Giuseppe
    He, Yongfeng
    SEMINARS IN CANCER BIOLOGY, 2023, 94 : 1 - 10
  • [7] Genetic Contribution to Nonsquamous, Non-Small Cell Lung Cancer in Nonsmokers
    Carr, Shamus R.
    Akerley, Wallace
    Cannon-Albright, Lisa A.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (07) : 938 - 945
  • [8] The development of immunotherapies for non-small cell lung cancer
    Salgaller, ML
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (03) : 265 - 278
  • [9] Afatinib for the treatment of non-small cell lung cancer
    Biello, Federica
    Maggioni, Claudia
    Rijavec, Erika
    Genova, Carlo
    Barletta, Giulia
    Gualco, Elisa
    Truini, Anna
    Coco, Simona
    Dal Bello, Maria Giovanna
    Vanni, Irene
    Alama, Angela
    Boccardo, Francesco
    Grossi, Francesco
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (11): : 1357 - 1364
  • [10] BRAF Inhibitors in Non-Small Cell Lung Cancer
    Sforza, Vincenzo
    Palumbo, Giuliano
    Cascetta, Priscilla
    Carillio, Guido
    Manzo, Anna
    Montanino, Agnese
    Sandomenico, Claudia
    Costanzo, Raffaele
    Esposito, Giovanna
    Laudato, Francesca
    Damiano, Simona
    Forte, Cira Antonietta
    Frosini, Giulia
    Farese, Stefano
    Piccirillo, Maria Carmela
    Pascarella, Giacomo
    Normanno, Nicola
    Morabito, Alessandro
    CANCERS, 2022, 14 (19)